Frank S. Menniti

TL;DR: This review discusses International Union of Basic and Clinical Pharmacology glutamate receptor nomenclature, structure, assembly, accessory subunits, interacting proteins, gene expression and translation, post-translational modifications, agonist and antagonist pharmacology, allosteric modulation, mechanisms of gating and permeation, roles in normal physiological function, as well as the potential therapeutic use of pharmacological agents acting at glutamate receptors.

TL;DR: CP-101,606 was safe, generally well tolerated, and capable of producing an antidepressant response without also producing a dissociative reaction, andagonism of the NR2B subtype of the N-methyl-D-aspartate receptor may be a fruitful target for the development of a new antidepressant with more robust effects and a faster onset.

TL;DR: The current state of the art in the burgeoning field of phosphodiesterase pharmacology in the CNS is reviewed, with a focus on the treatment of psychiatric and neurodegenerative disorders.

TL;DR: Data suggest a role for PDE10A in regulating activity within both the striatonigral and striatopallidal pathways, and a second, distinct function for the enzyme in these regions.

TL;DR: Findings provide evidence that cGMP and cAMP signaling cooperate in maintaining meiotic arrest via regulation of PDE3A and that a decrease in cG MP in the somatic compartment is one of the signals contributing to meiotic maturation.